Editas Medicine Presents at Barclays 28th Annual Global Healthcare Conference, Discussing CRISPR Therapeutics Approach

Editas Medicine, a company that uses in vivo CRISPR therapeutics, is presenting at the Barclays 28th Annual Global Healthcare Conference. CEO Gilmore O'Neill and CFO Amy Parison discuss the company's approach, which involves using CRISPR to make edits in noncoding DNA to increase the levels of disease-mitigating proteins. One example is EDIT-401, which has the potential to reduce LDL cholesterol levels by 90%, potentially transforming cardiovascular disease management.